- The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective2023 | Second Faculty of Medicine
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma2015 | First Faculty of Medicine
- Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock2019 | First Faculty of Medicine, Second Faculty of Medicine
- Uzlinové syndromy - zaměřeno na Castlemanovu chorobu2021 | First Faculty of Medicine
